Abstract: The presence of major IAS-USA mutations (L100I, K101E/H/P and Y181C/I/V) reduced the treatment response at week 24.
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
PMID: 19734799
2009
Journal of acquired immune deficiency syndromes (1999)
Abstract: 7 of 20 patients failing an NNRTI-containing regimen had minority variants with major etravirine-associated NNRTI-resistant mutations (P = 0.03, Fisher exact test): Y181C (7.0%), Y181C (3.6%) + G190A (3.2%), L100I (14%), L100I (32%) + 190A (5.4%), K101E (3.8%) + G190A (4.9%), K101E (4.0%) + G190S (4.8%), and G190S (3.1%).
Result: Among the 12 samples with NNRTI-resistance mutations, seven had a total of 11 major etravirine-resistance mutations including L100I (n=2),
Efavirenz: a decade of clinical experience in the treatment of HIV.
PMID: 19767318
2009
The Journal of antimicrobial chemotherapy
Discussion: G190A, Y181C and K101E) while only 1.1% had four or more such mutations.
Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Abstract: The resistance mechanism can be NNRTI-dependent as is the case for K101E where either indirect (nevirapine) or direct effects (efavirenz) apply.
Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.
PMID: 18582198
2008
The Journal of infectious diseases
Table: K101E
HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso.
PMID: 18667925
2008
Journal of acquired immune deficiency syndromes (1999)
Abstract: Some resistance mutations, notably D67N/G, K70R and L210W (thymidine analogue mutations-TAMs); K101E, V179E in RT, 154V, V82A/T/F and L90M in PR were significantly higher among CRF06_cpx than CRF02_AG strains (P < 0.05).
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
Abstract: The most frequent mutations were G190A (230%), Y181C (23%) and K101E (14.1%).
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
PMID: 18684096
2008
The Journal of infectious diseases
Table: K101E
Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
PMID: 18844463
2008
AIDS research and human retroviruses
Abstract: K101E and G190S together tend to decrease susceptibility to all nucleoside RT inhibitors, but the K103N mutation had little effect on nucleoside RT inhibitor susceptibility.
Abstract: In virus strains with the nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations K101E and G190S, the L74V mutation increased replication capacity, consistent with published observations, but replication capacity was decreased in strains without NNRTI resistance mutations.
Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
HIV mutation literature information.
PMID: 
2009
HIV medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT